Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Receives Average Recommendation of "Hold" from Brokerages

Zimmer Biomet Holdings, Inc. (NYSE:ZBH - Get Free Report) has earned an average recommendation of "Hold" from the twenty-one research firms that are currently covering the firm, Marketbeat.com reports. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $111.53.

Several analysts have issued reports on the company. Wells Fargo & Company dropped their target price on Zimmer Biomet from $113.00 to $98.00 and set an "equal weight" rating for the company in a report on Tuesday, May 6th. Barclays decreased their target price on Zimmer Biomet from $118.00 to $112.00 and set an "underweight" rating on the stock in a research note on Monday, February 10th. Needham & Company LLC reaffirmed a "hold" rating on shares of Zimmer Biomet in a research report on Friday, February 7th. Robert W. Baird cut their target price on Zimmer Biomet from $130.00 to $115.00 and set an "outperform" rating on the stock in a research report on Tuesday, May 6th. Finally, BTIG Research reissued a "buy" rating on shares of Zimmer Biomet in a research report on Monday, April 14th.

Institutional Trading of Zimmer Biomet

Several hedge funds have recently modified their holdings of ZBH. Vanguard Group Inc. raised its holdings in Zimmer Biomet by 0.7% during the first quarter. Vanguard Group Inc. now owns 23,052,925 shares of the medical equipment provider's stock worth $2,609,130,000 after purchasing an additional 166,763 shares during the last quarter. Dodge & Cox grew its position in Zimmer Biomet by 2.3% during the first quarter. Dodge & Cox now owns 19,564,454 shares of the medical equipment provider's stock valued at $2,214,305,000 after acquiring an additional 446,018 shares during the period. Price T Rowe Associates Inc. MD grew its position in Zimmer Biomet by 1.2% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider's stock valued at $1,559,147,000 after acquiring an additional 176,337 shares during the period. Ameriprise Financial Inc. grew its position in Zimmer Biomet by 236.0% during the first quarter. Ameriprise Financial Inc. now owns 4,568,287 shares of the medical equipment provider's stock valued at $517,039,000 after acquiring an additional 3,208,596 shares during the period. Finally, Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 5.9% in the fourth quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider's stock worth $417,814,000 after buying an additional 218,688 shares during the period. 88.89% of the stock is owned by institutional investors and hedge funds.

Zimmer Biomet Stock Performance

NYSE:ZBH traded up $0.36 during trading hours on Wednesday, reaching $91.82. The company had a trading volume of 1,265,442 shares, compared to its average volume of 1,797,707. Zimmer Biomet has a 1-year low of $89.22 and a 1-year high of $116.71. The firm has a market cap of $18.17 billion, a PE ratio of 20.63, a price-to-earnings-growth ratio of 1.95 and a beta of 0.78. The business's 50 day moving average price is $98.78 and its 200-day moving average price is $104.41. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99.

Zimmer Biomet (NYSE:ZBH - Get Free Report) last issued its quarterly earnings results on Monday, May 5th. The medical equipment provider reported $1.81 EPS for the quarter, topping the consensus estimate of $1.77 by $0.04. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. The firm had revenue of $1.91 billion during the quarter, compared to analysts' expectations of $1.89 billion. During the same period in the previous year, the business earned $1.94 earnings per share. The firm's revenue for the quarter was up 1.1% on a year-over-year basis. Research analysts forecast that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, July 31st. Stockholders of record on Thursday, June 26th will be issued a $0.24 dividend. The ex-dividend date of this dividend is Thursday, June 26th. This represents a $0.96 annualized dividend and a dividend yield of 1.05%. Zimmer Biomet's dividend payout ratio is currently 21.24%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.